ELGX - Endologix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.88
-0.17 (-2.81%)
At close: 4:00PM EDT

5.88 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close6.05
Open6.04
Bid5.88 x 1200
Ask5.95 x 800
Day's Range5.76 - 6.04
52 Week Range5.20 - 67.20
Volume149,337
Avg. Volume484,843
Market Cap60.846M
Beta (3Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-9.07
Earnings DateMay 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.82
Trade prices are not sourced from all markets
  • Business Wire9 days ago

    Endologix, Inc. to Announce First Quarter 2019 Financial Results on May 2, 2019

    Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2019 after the market close on Thursday, May 2, 2019. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call, dial 855-327-6838 (domestic) or 631-891-4304 (international) and refer to the passcode 10006610.

  • 5 Stocks to Profit From (Legal) Insider Buying Signals
    InvestorPlace9 days ago

    5 Stocks to Profit From (Legal) Insider Buying Signals

    When I am analyzing a company to see if it could potentially be a good long-term investment, I always research what the insiders are doing. It goes without saying that they probably have a much better idea of what is happening in the company than most analysts and they certainly know more about it than I do. I especially like to see what they are doing after their company's stock has fallen dramatically.I am not implying that there is anything illicit or illegal going on. When an insider wants to buy or sell their company's stock they can, as long as they follow very strict procedures. For instance, they have to file their intent to buy or sell with the SEC, and they are subject to "blackout periods," which are times in which they cannot trade the stock.For example, an insider may be prohibited from buying or selling the stock in the thirty days before or after the earnings release is due to be reported.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhat's more, an officer or a director of a company may decide to sell their stock for many reasons. They could need to raise money for tuitions, mortgages, weddings or even divorce settlements. But the insiders only buy for one reason: if they believe that the stock is undervalued and that it will eventually trade at a higher price where they can make a profit. * 7 Mid-Cap Stocks to Find the Market's Sweet Spot The following stocks have experienced such insider buying, and as such, are worthy of further inspection: EQT Corp (EQT) Click to Enlarge EQT Corp. (NYSE:EQT, $21.61) deals with natural gas in the Appalachian area. You may have never heard of EQT corporation, but you have probably used their products, as it's the largest producer of natural gas in the United States.Insider buying at the EQT Corporation has been prolific. The President, Robert McNally, bought almost 21,000 shares on March 29 at an average price of $20.80. He spent $200,000. The Executive Vice President, Erin Centofanti, bought almost 8,000 shares on March 29 at $20.83. Sue Smith, the CFO, paid $19.75 for 6,000 shares on March 14.Back in February Jonathon Lushko, the General Counsel and a Senior VP of the company, purchased almost 8,000 shares on the open market at an average price of $19.04. That is an investment of almost $150,000. In addition, the Senior VP of Human Resources, David Smith, invested more than $300,000 when he purchased 16,800 shares of the stock at an average price of $19.06.It is always interesting to see if and when the insiders buy their company stock after it has sold off significantly. In this case, the price of EQT has fallen about 50% in less than a year. This could be the reason why these insiders decided to invest. The stock is currently trading around $21.61, so they have already profited nicely.The analysts on Wall Street seem to like this stock as well. According to MarketWatch, twenty firms follow it on a research basis. Two of them have it rated as overweight, eleven have a buy rating on it, six rate it as holds and there's just one sell recommendation. The average target price is $25.40, which is about 20% higher than where it is currently trading. RumbleOn (RMBL) Click to Enlarge RumbleOn, Inc. (NASDAQ:RMBL, $5.60) is an e-commerce platform that is designed to help consumers and dealers finance, buy and sell used cars.Denmar Dixon is a member of the Board of Directors of RumbleOn. Mr. Dixon purchased 50,000 shares at $4.76 in early April. He also made considerable purchases early last year before the stock rallied. Back then, it was trading around the same levels that it currently is.The stock more than doubled when it traded above $10 in September and October. Mr. Dixon must have been feeling pretty good. But then it went into freefall and lost more than 50% of its value by December. * 10 Stocks That Are Screaming Buys Right Now This company is followed on a research basis by six companies. The average rating is a buy and the average target price is $9.90, which is more than 40% higher than where it is currently trading. Endologix (ELGX) Click to Enlarge Endologix, Inc. (NASDAQ:ELGX, $6.99) performs research and development and manufactures devices that treat aortic diseases. Its portfolio of products includes AFX Endovascular AAA System, Nellix and Ovation.On April 3, it was announced that the CEO, John Onopchenko, invested $200,000 when he purchased just over 30,000 shares. This increased his personal holdings in the stock by almost 40%. The CFO, Vaseem Mahboob, invested $100,000 of his personal money when he acquired 15,000 shares. In addition, two of the company's directors bought and additional 25,000 shares. These shares were all purchased at an average price of $6.61.Endologix has lost more than 90% of its value over the past year. They have recently announced that they are going to restructure their debt. This could be a good thing, or it could be a sign of desperation. The insider buying may mean that the insiders think that the restructuring will work.According to MarketWatch, nine firms follow this stock on a research basis. One has a buy rating on it, one has a sell rating and the other nine consider it a hold. The average target price is $10.30, which is significantly higher than where it is currently trading. This makes me wonder why seven firms have a hold on a stock that they feel is undervalued by 35%. Walgreens (WBA) Click to Enlarge You've probably been to Walgreens (NYSE:WBA, $54.69). It's one of the largest pharmacies in the country, with retail and pharmacy operations both domestically and on an international stage. The company was founded in 1901 and is headquartered in Deerfield, IL.Co-Chief Operating Officer Ms. Omella Barra may think that the recent selling in WBA is overdone. She invested nearly $1 million of her own money when she purchased 18,000 shares at an average price of $54.50 on April 3.WBA has had some issues lately. The company has sold off considerably because the two most recent earnings releases disappointed investors. The stock has fallen about 35% since November and it is trading at the lowest level that it has been at since 2014. Time will tell if there will be more insider buying. * The 7 Best Long-Term Stocks for 2019 And Beyond This company is widely followed on Wall Street. According to Marketwatch.com, 26 firms cover it. The average analyst rating is a hold and the average price target is $62.50. It is currently trading just under $55. Chaparral Energy (CHAP) Click to Enlarge Chaparral Energy, Inc. (NYSE:CHAP, $5.58) is in the natural gas and oil exploration and production (E&P) business. Specifically, CHAP makes its money on deposits of Stack, Meramec and Osage, Oswego and Woodford located in Oklahoma and the Texas Panhandle. Founded by Mark A. Fischer and Charles A. Fischer in April 1988, Chaparral Energy is headquartered in Oklahoma City, OK.The CEO of the company, K. Earl Reynolds, purchased 7,100 shares of CHAP on March 29th at an average price of $4.64. A large institutional holder, Strategic Value Partners, also recently acquired 900,000 shares at a price of $4.45.The stock has fallen by more than 75% over the past year. Mr. Reynolds and the portfolio managers at Strategic Value Partners must believe that the stock is very attractive at these prices.Wall Street likes this stock as well. It is followed by four firms that follow the company on a research basis. The average rating is a buy and the average target price is $18.38. That is more than 300% higher than where it is currently trading.As of this writing, Mark Putrino did not hold any positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post 5 Stocks to Profit From (Legal) Insider Buying Signals appeared first on InvestorPlace.

  • GuruFocus.com16 days ago

    Weekly CFO Buys Highlight

    Recent buys from company CFOs

  • GuruFocus.com21 days ago

    Endologix Inc (ELGX) CEO and Director John Onopchenko Bought $199,999 of Shares

    CEO and Director of Endologix Inc (NASDAQ:ELGX) John Onopchenko bought 30,257 shares of ELGX on 04/03/2019 at an average price of $6.61 a share.

  • GuruFocus.com23 days ago

    Endologix Inc (ELGX) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Endologix Inc develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. Its products are intended for the treatment of abdominal aortic aneurysms. Warning! GuruFocus has detected 4 Warning Signs with ELGX.

  • Business Wire24 days ago

    Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants

    Endologix, Inc. (ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into a definitive agreement to raise approximately $52 million gross cash proceeds through the issuance of approximately 7.9 million new shares of the Company’s common stock at a purchase price of $6.61 per share. The Company’s net proceeds, after payment of estimated financial advisor fees but before other transaction expenses, is expected to be approximately $49 million. In a separate transaction, the Company also entered into an exchange agreement with two holders of the Company’s 3.25% Senior Convertible Notes due 2020 (the “3.25% Notes”), pursuant to which these investors exchanged an aggregate of approximately $73 million of 3.25% Notes plus accrued interest for approximately $67 million of 5.0% Convertible Senior Notes due 2024 (the “5.0% Notes”) at the rate of $900 principal amount of 5.0% Notes for every $1000 principal amount of 3.25% Notes.

  • Business Wirelast month

    Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Endologix, Inc. (ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to nine newly hired employees (the “Awardees”). The awards were approved by the Company’s Compensation Committee, which is comprised of independent Directors, on March 13, 2019, as an inducement material to the Awardees’ entry into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4). The inducement grants to the Awardees consisted of options (the “Options”) to purchase up to an aggregate of 46,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at an exercise price of $6.76 per share.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on March 5) AstraZeneca plc (NYSE: AZN ) Biohaven Pharmaceutical ...

  • Business Wire2 months ago

    Endologix Announces Approval of Reverse Stock Split

    Endologix, Inc. (the “Company”) (ELGX) previously announced that a proposal was approved at its Special Meeting of Stockholders, held February 22, 2019, authorizing its Board of Directors to amend the Company's certificate of incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio not less than 1-for-5 and not greater than 1-for-10 (inclusive), with the exact ratio to be set within that range by the Company’s Board of Directors. The number of authorized shares of common stock would remain at 170 million shares, and the number of authorized shares of preferred stock would remain at 5 million shares. The Company’s Board of Directors had previously directed that the proposal be submitted to the stockholders for approval and has subsequently approved the reverse stock split at a ratio of 1-for-10.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ELGX earnings conference call or presentation 25-Feb-19 9:30pm GMT

    Q4 2018 Endologix Inc Earnings Call

  • What Should We Expect From Endologix, Inc.’s (NASDAQ:ELGX) Earnings Over The Next Few Years?
    Simply Wall St.2 months ago

    What Should We Expect From Endologix, Inc.’s (NASDAQ:ELGX) Earnings Over The Next Few Years?

    Endologix, Inc.'s (NASDAQ:ELGX) released its most recent earnings update in December 2018, which suggested company earnings became less negative compared to the previous year's level - great news for investorsRead More...

  • Business Wire2 months ago

    Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results

    Endologix, Inc. , a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the fourth quarter and fiscal year ended December 31, 2018.

  • ACCESSWIRE2 months ago

    Endologix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Endologix, Inc. (NASDAQ: ELGX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019 at 4:30 PM ...

  • All You Need to Know About Endologix (ELGX) Rating Upgrade to Buy
    Zacks2 months ago

    All You Need to Know About Endologix (ELGX) Rating Upgrade to Buy

    Endologix (ELGX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Endologix (ELGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks2 months ago

    Endologix (ELGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Endologix (ELGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Micron Technology, Endologix, Group 1 Automotive, Dana, MACOM Technology Solutions, and Fred's — Future Expectations, Projections Moving into 2019

    NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • WellCare Health (WCG) Q4 Earnings Beat Estimates, Soar Y/Y
    Zacks3 months ago

    WellCare Health (WCG) Q4 Earnings Beat Estimates, Soar Y/Y

    WellCare Health's (WCG) Q4 earnings gain from Meridian buyout and growth in membership.

  • Humana's (HUM) Q4 Earnings Surpass Estimates, Improve Y/Y
    Zacks3 months ago

    Humana's (HUM) Q4 Earnings Surpass Estimates, Improve Y/Y

    Humana's (HUM) fourth-quarter earnings gain on the back of Medicare Advantage membership growth and operating efficiencies.

  • Centene's (CNC) Earnings Top Estimates in Q4, Surge Y/Y
    Zacks3 months ago

    Centene's (CNC) Earnings Top Estimates in Q4, Surge Y/Y

    Centene's (CNC) Q4 earnings ride high on robust revenues, solid acquisitions and stronger Health Insurance Marketplace business.

  • Business Wire3 months ago

    Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on February 25, 2019

    Endologix, Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal year 2018 after the market close on Monday, February 25, 2019. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. This conference call will also be webcast and can be accessed from the “Investors” section of the Company’s website at www.endologix.com.

  • Business Wire3 months ago

    Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

    Endologix® Inc. (ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been suspended by its Notified Body, GMED, following a voluntary recall and Field Safety Notification (FSN) issued by Endologix on January 4, 2019. “The notification from GMED is a regulatory action and is not in response to any new information beyond our recent FSN,” said Dr. Matt Thompson, Chief Medical Officer of Endologix. “This action is consistent with our previously articulated plans for the Nellix System and does not affect other Endologix products.

  • Business Wire3 months ago

    Endologix Appoints John D. Zehren as Chief Commercial Officer

    Endologix, Inc. (ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John D. Zehren as the Company’s Chief Commercial Officer, effective as of January 7, 2019 (the “Effective Date”). Mr. Zehren brings to Endologix more than twenty years of commercial, sales and marketing, and business development experience in the medical device industry. Earlier in his distinguished career, Mr. Zehren spent over a decade at Edwards Lifesciences, the last four years of which were in the role of Vice President of Sales and Marketing.